A practitioner-built framework for deploying AI responsibly across Medical Affairs and Commercial functions in regulated pharmaceutical environments — informed by 26 years governing these capabilities at enterprise scale.
In pharma and life sciences, AI does not fail because the models are wrong. It fails because the governance is missing. The data is fragmented. The ownership is unclear. The compliance framework was designed for deterministic software, not adaptive machine learning systems.
The organizations that are successfully moving AI from pilot to production share one trait: they built the governance model before they built the solution. Functional ownership defined before architecture. Signal classification rules agreed before data shared. Measurement frameworks established before deployment.
This is the operating principle behind every MarAITech concept — governance as the foundation, not the afterthought.
Medical Affairs defines the problem, intended use, approved source set, and human review requirements before any technology is selected or architecture built.
The level of data abstraction is the primary compliance mechanism. Synthesized scientific themes may cross functional firewalls. Raw field notes do not.
Every AI-informed decision must be traceable end to end — from the field interaction through the abstraction and approval, to the decision it ultimately informed.
AI augments human judgment; it does not replace it. Critical decision points — MLR review, medical leadership approval, compliance sign-off — remain human-owned.
AI governance requires representation from quality assurance, data science, IT, regulatory affairs, and Medical Affairs from day one — not brought in at implementation.
All MarAITech demonstrations use clearly labeled illustrative fictional data. No real patient, HCP, or commercial data is used in any concept demonstration.
Connecting Medical Affairs and Commercial AI requires a governance model that enables insight sharing without compromising the independence regulation requires. MarAITech's three-step model:
Medical Affairs defines the workflow problem, intended use, approved source set, acceptable failure boundaries, and human review points before any data architecture is designed.
Agree explicitly on which signals cross the Medical-Commercial firewall and which remain private. Synthesized scientific themes approved by medical leadership may cross. Raw MSL field notes do not. The classification rule is documented, versioned, and auditable.
Build traceability across the full chain — from field interaction through abstraction and approval to commercial decision and measurable outcome. Traceability is what turns proxy metrics into real outcome measurement and makes the governance model auditable under regulatory scrutiny.
MarAITech concepts are developed with awareness of the evolving regulatory environment governing AI in life sciences. Key frameworks informing our approach:
| Framework | Scope | Key Implication |
|---|---|---|
| FDA Draft Guidance on AI (Jan 2025) | US — drug and biological product submissions | Credibility, validation, and change control requirements for AI used in regulatory decision-making |
| EU AI Act (Aug 2025 / Aug 2026) | EU — high-risk AI systems in healthcare | Mandatory risk management, technical documentation, and conformity assessment for high-risk AI |
| GxP Data Integrity (FDA / EMA / MHRA) | Global — regulated manufacturing and clinical environments | ALCOA principles apply to AI-generated outputs — complete, consistent, accurate, legible, original |
| GDPR / Data Privacy | EU and applicable global jurisdictions | HCP and patient data handling, consent frameworks, cross-border data flows |
| ABPI Code / PhRMA Guidelines | UK / US — promotional and medical communications | AI-generated content for HCP engagement must comply with promotional guidelines and require human review |
Important notice: This page provides general educational information about AI governance principles relevant to pharmaceutical and life sciences organizations. It does not constitute legal, regulatory, or compliance advice. Organizations should consult qualified legal and regulatory affairs professionals before deploying AI systems in regulated environments. MarAITech LLC is an AI enablement advisory and concept development firm, not a legal or regulatory services provider.
Every solution concept developed under the MarAITech framework adheres to the following commitments:
No real patient or HCP data. All demonstrations use fictional illustrative data clearly labeled as such. No personally identifiable information, no real prescribing data, no real clinical outcomes.
No promotional intent. MarAITech concepts are built to demonstrate capability frameworks, not to promote specific pharmaceutical products or make claims about real drugs.
Transparency about AI involvement. Every AI-generated output in MarAITech concepts is identified as AI-generated. Human review requirements are explicitly built into every workflow design.
Governance before architecture. No MarAITech concept proceeds to technical design without functional ownership, intended use, and human review requirements being defined first.
If you have questions about how MarAITech approaches AI governance, responsible AI deployment, or the regulatory landscape for pharma AI, we welcome the conversation.
Start a conversation